April 12, 2025 – Meishu Biotech, a trailblazer in innovative healthcare solutions, proudly announces the launch of Osteahenz, a revolutionary brand in the orthopedic segment. Backed by a patent-pending formula, Osteahenz introduces the Synoregen Complex, featuring the cutting-edge MRELF MultiCollagen Peptide combined with the potent antioxidant Resveratrol. This groundbreaking formulation is designed to support bone health by promoting the activity of osteoblasts (bone-forming cells) and regulating osteoclasts (bone-resorbing cells), offering a new standard in orthopedic care.
A New Era in Bone Health
Osteahenz is crafted to address the growing need for effective, science-driven solutions for bone and joint health. With an aging global population and increasing prevalence of conditions like osteoporosis and osteoarthritis, Meishu Biotech’s innovative approach sets Osteahenz apart as a game-changer. The product targets individuals seeking to maintain strong bones, enhance mobility, and support long-term skeletal wellness.
At the heart of Osteahenz lies the Synoregen Complex, a patent-pending blend that harnesses the synergistic power of MRELF MultiCollagen Peptide and Resveratrol. This unique combination works to optimize bone remodeling, a critical process where osteoblasts build new bone and osteoclasts remove old bone, ensuring skeletal strength and resilience.
The Science Behind Synoregen Complex
The MRELF MultiCollagen Peptide is a proprietary blend of collagen types specifically formulated to support bone matrix integrity. Collagen is a key structural protein in bones, providing the framework for calcium and other minerals. By delivering a bioavailable source of multi-collagen peptides, Osteahenz enhances osteoblast activity, promoting bone formation and improving bone density.
Complementing this is Resveratrol, a powerful polyphenol known for its antioxidant and anti-inflammatory properties. Research suggests Resveratrol supports bone health by stimulating osteoblast differentiation and inhibiting excessive osteoclast activity, which can lead to bone loss. This dual-action approach helps maintain a healthy balance in bone remodeling, making Osteahenz a standout in orthopedic supplementation.
“Our mission at Meishu Biotech is to push the boundaries of science to improve lives,” said , Chief Scientific Officer at Meishu Biotech. “With Osteahenz and its Synoregen Complex, we’re delivering a product that not only supports bone health but also empowers individuals to live active, fulfilling lives with confidence in their skeletal strength.”
please visit for more information : www.osteahenz.com

Meishu Biotech, a leader in biotechnology and pharmaceuticals, has unveiled OSTEAHENZ, a breakthrough treatment for osteoporosis. This patent-applied product is India’s first in the orthopedic segment and promises a transformative approach to addressing a condition that affects millions of people, particularly the elderly.

Osteoporosis, a condition characterized by fragile bones prone to fractures, occurs due to an imbalance between bone formation and bone breakdown. OSTEAHENZ addresses this issue with a unique dual-action mechanism. It enhances the activity of osteoblasts, the cells responsible for building new bone tissue, while simultaneously reducing the activity of osteoclasts, which break down bone tissue. This innovative approach not only increases bone density but also ensures stronger and healthier bones, reducing the risk of debilitating fractures.

The launch of OSTEAHENZ marks a major step forward in bone health management. With its ability to significantly reduce fracture risk, the product offers patients a new lease on life by enabling them to maintain an active and independent lifestyle without the constant fear of bone-related injuries. It is also tailored to meet individual patient needs, considering factors like age and the severity of the condition, ensuring a personalized approach to treatment.

Meishu Biotech’s commitment to research and innovation is evident in the development of OSTEAHENZ. The product is a result of years of meticulous research and rigorous clinical studies, showcasing the company’s dedication to addressing unmet medical needs. By focusing on creating solutions for critical segments like orthopedics, oncology, neurology, and infertility, Meishu Biotech is setting new benchmarks in the pharmaceutical industry.

OSTEAHENZ also highlights India’s growing prominence in global pharmaceutical innovation. As a product developed entirely in India, it is a testament to the country’s capabilities in advancing healthcare solutions that cater to global challenges.

With the launch of OSTEAHENZ, Meishu Biotech has once again demonstrated its customer-focused approach and its mission to improve lives through innovative, research-driven products. Looking ahead, the company plans to introduce new treatments in neurology, gastroenterology, and orthopedics, reinforcing its position as a leader in biotechnology and pharmaceuticals.

As the product begins to reach patients across the country, especially in key markets .
OSTEAHENZ is poised to make a profound impact on the lives of those living with osteoporosis, setting a new standard for effective bone health treatment.